Bioburden Testing Workflow | GMPify Training

🦠

Bioburden Testing - Quantifying Microbial Load Against Route-Specific Limits

Bioburden testing quantifies the total viable microbial population present in or on a nonsterile product, raw material, or in-process sample. USP <61> defines the test methodology while USP <1111> sets acceptance criteria that vary by the product's intended route of administration, since a limit appropriate for a topical cream is not appropriate for an oral aqueous suspension. Unlike sterility testing, bioburden testing does not require the complete absence of microorganisms, only that levels and specified organisms remain within the criteria appropriate to how the product will be used.

USP <61> · USP <1111> · EU GMP Annex 1 2022 · 21 CFR 211.113

USP <61>

USP <1111>

EU GMP Annex 1 2022

21 CFR 211.113

Oral Aqueous Preparations

Aqueous solutions and suspensions for oral use. Lower acceptance limits reflect the higher risk profile of an aqueous matrix supporting microbial growth.

TAMC: 10^2 CFU/mL or g

TYMC: 10^1 CFU/mL or g

Absence: E. coli

Oral Nonaqueous Preparations

Tablets, capsules, and other nonaqueous oral dosage forms. Higher acceptance limits reflect the lower water activity that limits microbial proliferation.

TAMC: 10^3 CFU/g

TYMC: 10^2 CFU/g

Absence: E. coli

Topical, Mucosal, Inhalation

Cutaneous, nasal, otic, oromucosal, and inhalation products. Additional objectionable organism testing applies based on the route and site of application.

TAMC: 10^2 CFU/g or mL

TYMC: 10^1 CFU/g or mL

Absence: S. aureus, P. aeruginosa

Special Populations

Products labeled for use in infants, or applied to severely compromised skin, warrant consideration of stricter criteria per USP <1111> guidance notes.

Basis: Risk-based, per USP <1111>

Consideration: Vulnerable populations

Approach: Tighter internal limits

Phase 1

Sample and Method Selection

1Identify the applicable USP <1111> category

Route of administration determines which acceptance criteria table applies. This decision is made once per product and documented in the specification.

USP <1111>

↓

2Select the enumeration method

Pour plate, spread plate, or membrane filtration method selected per USP <61> based on product characteristics and expected bioburden level.

USP <61>

↓

3Confirm method suitability

Method suitability testing demonstrates the product does not inhibit recovery of challenge organisms at the chosen dilution, repeated whenever formulation changes.

USP <61>

↓

4Prepare sample dilutions

Sample homogenized and diluted per the validated protocol to bring expected colony counts into the statistically valid countable range.

USP <61>

Phase 2

Test Execution

5Perform Total Aerobic Microbial Count

TAMC quantifies total aerobic bacteria using Soybean-Casein Digest Agar, incubated at 30 to 35 degrees C for 3 to 5 days.

USP <61>

↓

6Perform Total Yeast and Mold Count

TYMC quantifies fungal organisms using Sabouraud Dextrose Agar, incubated at 20 to 25 degrees C for 5 to 7 days.

USP <61>

↓

7Test for specified objectionable organisms

Tests for E. coli, S. aureus, P. aeruginosa, Salmonella, or other organisms required by the product's USP <1111> category and any additional product-specific risk assessment.

USP <62> · USP <1111>

↓

Do TAMC, TYMC, and objectionable organism results meet the category criteria?

YES → Record and trend NO → Initiate investigation

Phase 3

Result Interpretation and Trending

8Calculate CFU per gram or milliliter

Raw colony counts converted to CFU/g or CFU/mL accounting for dilution factor, with results reported using the statistically valid countable plate range.

USP <61>

↓

9Trend results by product over time

Individual batch results trended against the product's historical baseline to detect gradual upward drift even while remaining within acceptance criteria.

ICH Q10

↓

10Compare across raw material lots and suppliers

Bioburden data from raw materials trended by supplier and lot to identify a supply chain source of increasing microbial load before it affects finished product.

ICH Q7

Phase 4

Investigation and Release Decision

11Investigate any exceedance or objectionable organism finding

Result exceeding acceptance criteria, or detection of a specified objectionable organism, triggers a full OOS investigation per 21 CFR 211.192 before a disposition decision is made.

21 CFR 211.192

↓

12QA release decision

Quality unit reviews the complete bioburden data package, including any investigation findings, before authorizing batch release.

21 CFR 211.22

↓

13Retain documentation and update trend records

Complete raw data, calculations, and any investigation records retained per site requirements, with results added to the product's ongoing trend dataset.

21 CFR 211.180

Acceptance Criteria Structure (USP <1111>)

TAMC - Total Aerobic Microbial Count

Quantifies total viable aerobic bacteria. Acceptance criteria set independently for each USP <1111> product category based on route of administration.

USP <61> · USP <1111>

TYMC - Total Yeast and Mold Count

Quantifies total viable fungal organisms. Consistently set at a lower numeric limit than TAMC across every product category.

USP <61> · USP <1111>

Objectionable Organism Absence

Specified organisms such as E. coli, S. aureus, and P. aeruginosa must be absent in the tested sample quantity, regardless of the overall count result.

USP <1111>

OOS Investigation Response Steps

Step 1 - Confirm result validity Rule out contamination during sample handling, media quality issues, or incubation deviation before concluding a genuine product-related result.

Step 2 - Identify the recovered organism Species-level identification informs whether the finding is consistent with an environmental, raw material, or process-related source.

Step 3 - Review raw material and process history Examine raw material bioburden data, water system results, and any deviations from the batch's manufacturing history.

Step 4 - Assess batch and related batch impact Determine whether other batches manufactured with the same raw material lot or process conditions require evaluation.

Step 5 - Reach and document a disposition decision Conclude root cause and disposition with full documentation supporting the release, rejection, or rework decision.

Sampling Requirements

Representative sampling Samples drawn to represent the batch, with additional sampling of raw materials at receipt and in-process material at defined process stages where risk warrants it.

Aseptic sample handling Sample collection and preparation performed to avoid introducing extraneous contamination that could produce a false elevated result.

Dilution scheme validated Dilution series designed to bring expected counts into the countable range without introducing dilution-related recovery bias.

Retained samples for investigation Sufficient sample retained where practical to support repeat testing if an initial result requires investigation.

Method Verification and Control Requirements

Method Suitability Test Confirms the product formulation and chosen dilution do not inhibit recovery of low levels of challenge microorganisms, repeated on formulation change.

Growth Promotion Testing Each lot of agar media undergoes growth promotion testing with reference organisms before use in routine bioburden testing.

Negative Control Confirms the testing process, environment, and diluent did not introduce contamination independent of the sample itself.

Statistically Valid Countable Range Plates within the countable range, typically 25 to 250 colonies for standard plate methods, are used for CFU calculation to maintain statistical validity.

Incubation Condition Control Incubator temperature and duration monitored and documented to confirm conditions met the validated method throughout the incubation period.

Analyst Qualification Analysts performing bioburden testing are qualified through documented technique demonstration before performing routine testing.

Equipment Calibration Balances, pipettes, and incubators used in testing maintained on a routine calibration and preventive maintenance schedule.

Reference Organism Traceability Challenge organisms used in method suitability and growth promotion testing traceable to a recognized culture collection with documented passage history.

Never do this

Apply a single universal acceptance limit across all product categories regardless of route of administration. Skip method suitability testing after a formulation change. Report results from plates outside the statistically valid countable range without documented justification. Close an exceedance without root cause investigation.

TAMC vs TYMC

TAMC quantifies aerobic bacteria using conditions favoring bacterial growth. TYMC quantifies yeast and mold using conditions favoring fungal growth. Both are required and evaluated against separate acceptance criteria within the same product category.

Bioburden vs sterility testing

Bioburden testing quantifies microbial load against a route-appropriate limit for nonsterile products. Sterility testing verifies the complete absence of viable organisms for products required to be sterile. The two tests serve different regulatory purposes and are not interchangeable.

Key regulations

USP <61> - microbiological examination methodology. USP <1111> - acceptance criteria by product category. EU GMP Annex 1 2022 - microbial control expectations. 21 CFR 211.113 - control of microbiological contamination.